I find creative, outside of the box solutions to allow companies to close on their sophisticated collaborative agreements.
Sumantha "Sumi" Sedor has experience in a broad range of matters, including assisting life sciences, technology, energy and emerging companies with licensing transactions, distribution and supply arrangements, product acquisitions, joint ventures, strategic alliances and corporate partnering, along with experience in corporate restructuring, venture capital, corporate compliance and disclosure, corporate governance and other general corporate matters. Sumi also assists family offices and high net worth individuals in similar corporate undertakings.
Elisabeth Haub School of Law at Pace University, J.D., John Jay Legal Scholar and Merit Scholar, 2005
Boston College, Carroll School of Management, B.S., 2000
Bar and Court Admissions
BAR ADMISSIONS
New York
Experience
Advising and representing both domestic and international pharmaceutical companies in connection with various licensing agreements, distribution and supply arrangements, joint ventures, product acquisitions, authorized generic agreements, corporate restructuring, corporate governance and other various corporate matters.
Act as de facto General Counsel for life sciences, technology, energy and emerging companies handling essentially all corporate related legal matters, including negotiating and finalizing confidentiality agreements, master services agreements, material transfer agreements, options, sponsored research agreements, CRO agreements, clinical trial agreements, laboratory and clinical supply agreements, manufacturing and supply agreements, consultant agreements, construction agreements and other similar agreements.
Represented LigaChem Biosciences (KRX: 141080), a clinical stage biopharmaceutical company in:
two transactions involving the license of LigaChem technology to Ono Pharmaceutical (TSE/TYO: 4528), to grow Ono’s oncology portfolio:
an exclusive license to LCB97, a pre-clinical stage antibody-drug conjugate (ADC) aimed at being a first-in-class drug in the field of solid tumors, for upfront and milestone payments of up to US$700 million, plus tiered royalties; and
a research collaboration and license agreement to generate novel ADC candidates leveraging LigaChem’s ConjuAll™️ ADC platform, granting Ono an exclusive global right to ADC candidates to be generated against multiple targets selected by Ono, for a target exclusivity fee, milestone payments, and tiered royalties;
two exclusive worldwide antibody licensing deals with NovaRock Biotherapeutics for ADC Drug Development; and
a worldwide in-licensing transaction with Go Therapeutics for a new antibody platform designed for the development of ADCs.
its exclusive licensing agreement with CS Pharmaceuticals for a first-in-class PRS inhibitor ‘Bersiporocin’ in Greater China region; and
its exclusive license agreement with and equity investment in Vitalli Bio, a portfolio company of Aditum Bio, for the development and commercialization of a first-in-class new drug targeting Bruton's Tyrosine Kinase (BTK) and Interleukin-2-inducible T-cell kinase (ITK).
Represented a private biopharma company in connection with its purchase of the previously-owned rights to the anti-CD19 monoclonal antibody (mAb) budoprutug (SLRN119) from a public company.
Represented a private US pharmaceutical company on an alliance for a joint product launch with a US subsidiary of a public pharmaceutical company.*
Represented and assisted a Canadian pharmaceutical company and its international associated companies in expanding its pipeline by entering into an exclusive development, license and supply agreements with a public pharmaceutical company for the developmental stage formulation of epinephrine for emergency treatment of severe anaphylactic reactions.*
Represented a private US Pharmaceutical company on a research and licensing agreement a public pharmaceutical company for the purpose of discovering and developing a cure for psoriasis and other diseases.*
Represented and assisted a private US pharmaceutical company and its international associated company in expanding its pipeline by the development and execution of a novel US$500 million collaboration agreement/equity investment/line of credit transaction structure with a public pharmaceutical company.*
Represented and assisted a US pharmaceutical company and its international associated company in expanding its pipeline by the development and execution of a US$95 million collaboration agreement/equity investment transaction structure with a public pharmaceutical company.*
Represented the management of an aluminum company in its management buyout.*
Represented multiple investors in multiple venture capital rounds (Series A and Series B) in Blink Health.*
Represented multiple investors in multiple venture capital rounds (Series C, Series D and Bridge) in Achronix Semiconductor.*
Represented the largest shareholder of a publicly owned technology company in multiple PIPE financings.*
Represented one of the investors in the start-up financing of a biotechnology company that was developing products to diagnose and treat dry and wet Age-related Macular Degeneration (AMD).*
Represented a private US pharmaceutical company in the dissolution of a joint venture and corresponding new licensing and distribution arrangement.*
Represented a pharmaceutical company in the asset acquisition of a currently marketed branded product.*
Represented a pharmaceutical company in connection with authorized generic agreements of a currently branded product.*
* - Ms. Sedor handled the above representations prior to joining Foley Hoag
Other Events
"License-Out Negotiations with Global Pharma and Patent Strategies for Korean Companies," Korea Health Industry Development Institute’s Licensing & Intellectual Property Webinar (September 2025)
"Licensing," Foley Hoag FDA and Life Sciences Summit (May 2024)
"Foley Hoag Life Sciences Jumpstart Series: From Startup to Scale-Up," Foley Hoag Webinar (October 2023)
We use cookies to enhance user experience, improve functionality and performance, and for analysis of website traffic. By clicking “accept”, you agree to the use of cookies. For more information about our cookie policy and the information we collect, please review our Privacy Statement.
Foley Hoag
Email Disclaimer
Transmitting information to us by e-mail unilaterally does not establish an attorney-client relationship or impose an obligation on either the law firm or even the receiving lawyer to keep the transmitted information confidential. By clicking "OK," you acknowledge that we have no obligation to maintain the confidentiality of any information you submit to us unless we already represent you or unless we have agreed to receive limited confidential material/information from you as a prospective client. Thus, if you are not a client or someone we have agreed to consider as a prospective client, information you submit to us by e-mail may be disclosed to others or used against you.
If you would like to discuss becoming a client, please contact one of our attorneys to arrange for a meeting or telephone conference. If you wish to disclose confidential information to a lawyer in the firm before an attorney-client relationship is established, the protections that the law firm will provide to such information from a prospective client should be discussed before such information is submitted. Thank you for your interest in Foley Hoag.
